For research use only. Not for therapeutic Use.
Izeltabart(CAT: I040390) is a high-affinity humanized IgG1κ monoclonal antibody specifically designed to target ADAM9, a metalloproteinase commonly overexpressed in various solid tumors. Optimized for precise conjugation, Izeltabart serves as the antibody backbone for ADC development, notably IMGC‑936, an antibody–drug conjugate incorporating a maytansinoid payload via the DM21‑C linker. This ADC demonstrates potent cytotoxic effects against ADAM9-positive cancer cell lines and significant anti-tumor activity in xenograft models. Supplied as a colorless to light-yellow liquid at ≥ 95% purity, and suitable for site-specific conjugation, Izeltabart is ideal for advanced oncology research, ADC design, tumor-targeted therapy development, and mechanistic cancer studies.
CAS Number | 2642078-60-0 |
Purity | ≥95% |
Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |